Opinion on Healthcare Facilities and Providers in South and Central America

Published within

« | 1 | » »|

Type Product title / description Pub Price
Expert View
Expert View

Roche looks to maximize Genentech potential

Roche has initiated efforts to acquire all outstanding shares in Genentech for approximately $43.7 billion, having purchased 55.9% of the company in 1990. While Genentech has historically operated independently from its parent company, it remains to be seen whether the merger will damage an operating structure which has allowed the biotech firm to drive Roche's growth performance in recent years.

Published By Datamonitor
23 Jul 2008
Expert View
Expert View

Rising healthcare costs and the economic downturn continue to shape the healthcare landscape

Aging populations, a growing prevalence of chronic diseases, and greater use of expensive treatments are among the factors putting pressure on healthcare budgets in developed and developing markets. Consequently, countries are resorting to a range of strategies including pricing and reimbursement cuts and bolstering generic uptake, in turn exerting negative pressures on pharmaceutical companies.

Published By Datamonitor
19 Apr 2011
Expert View
Expert View

Immunization against S. aureus has potential in selected target groups

Staphylococcus aureus bacteria have become a key concern in both the hospital and community setting. The spread of resistant strains, such as MRSA, underlines the urgent need for new strategies to treat and prevent these infections. Prophylactic vaccination of target groups could be a useful tool, but prudent group selection combined with alternative prevention strategies, will be key to success.

Published By Datamonitor
17 Jul 2008
CommentWire
CommentWire

Celiac disease: improved diagnosis potential highlights untapped market

A new study has highlighted the benefit of routine antibody testing in suspected cases of celiac disease. While these data prove the merit of serological testing, awareness of the disease remains a significant issue. Indeed, with almost no treatment options available, the development of an effective pharmacological therapy offers the potential to reap significant returns from this untapped market.

Published By Datamonitor
21 Dec 2009

« | 1 | » »|

No help is available.